Pfizer gains FDA 'breakthrough' status for Xalkori
This article was originally published in Scrip
Executive Summary
The FDA has granted Pfizer's Xalkori (crizotinib) a breakthrough therapy designation as a potential treatment of patients with ROS1-positive non-small-cell lung cancer (NSCLC).